Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
Top Cited Papers
- 28 June 2002
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 100 (2) , 406-414
- https://doi.org/10.1182/blood.v100.2.406
Abstract
Chronic graft-versus-host disease (cGVHD) is the leading cause of late treatment-related deaths among recipients of allogeneic bone marrow and blood transplants. However, cGVHD is also associated with fewer relapses. We sought to determine whether severity of cGVHD predicts the magnitude of these effects. One impediment to such an analysis is the current limited/extensive grading system for cGVHD because this classification was designed to identify patients likely to benefit from systemic immune suppression and does not capture the severity of multiorgan involvement. We, therefore, first developed a grading system predictive for survival by using data from 1827 HLA-matched sibling allotransplant recipients reported to the International Bone Marrow Transplant Registry (IBMTR). We found Karnofsky performance score, diarrhea, weight loss, and cutaneous and oral involvement to be independent prognostic variables, from which we generated a grading scheme. We tested this scheme, the limited/extensive classification system, and a classification based on clinical impression of overall cGVHD severity (mild/moderate/severe) in parallel analyses of 1092 HLA-matched sibling transplant recipients from the IBMTR and 553 recipients of unrelated donor marrow from the National Marrow Donor Program. Presence of cGVHD was associated with fewer relapses (relative risk [RR], 0.5-0.6) but more treatment-related mortality (RR, 1.8-2.8) in the 3 analyses. No grading scheme correlated cGVHD severity with relapse rates, but all schemes predicted treatment-related mortality. Survival and disease-free survival of the most favorable cGVHD group in each scheme were similar, or better, than those of patients without cGVHD; these patients may not need aggressive or extended immune suppression.Keywords
This publication has 15 references indexed in Scilit:
- Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Société Française de Greffe de MoelleJournal of Clinical Oncology, 2000
- Long-Term Survival and Late Deaths after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1999
- A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapseTransplantation and Cellular Therapy, 1999
- Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control studyBone Marrow Transplantation, 1998
- A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled studyBone Marrow Transplantation, 1998
- Quality of life following bone marrow transplantation: a comparison of patient reports with population normsBone Marrow Transplantation, 1997
- Health and Functional Status of Long-Term Survivors of Bone Marrow TransplantationAnnals of Internal Medicine, 1997
- Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporineTransplantation Proceedings, 1997
- Antileukemic Effect of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1981
- Chronic graft-versus-host syndrome in manThe American Journal of Medicine, 1980